[go: up one dir, main page]

KR830007567A - 1, 2, 3, 4-테트라하이드로이소퀴놀린-3-카복실산의 치환아실 유도체의 제조방법. - Google Patents

1, 2, 3, 4-테트라하이드로이소퀴놀린-3-카복실산의 치환아실 유도체의 제조방법. Download PDF

Info

Publication number
KR830007567A
KR830007567A KR1019810003713A KR810003713A KR830007567A KR 830007567 A KR830007567 A KR 830007567A KR 1019810003713 A KR1019810003713 A KR 1019810003713A KR 810003713 A KR810003713 A KR 810003713A KR 830007567 A KR830007567 A KR 830007567A
Authority
KR
South Korea
Prior art keywords
tetrahydroisoquinoline
producing
carboxylic acid
substituted acyl
acyl derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019810003713A
Other languages
English (en)
Other versions
KR880001326B1 (ko
Inventor
루이스 훼플 밀톤
클러츠코 사일베스터
Original Assignee
토마스 디. 몰티테르노
워너 람벗 트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26889329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR830007567(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 토마스 디. 몰티테르노, 워너 람벗 트 캄파니 filed Critical 토마스 디. 몰티테르노
Publication of KR830007567A publication Critical patent/KR830007567A/ko
Application granted granted Critical
Publication of KR880001326B1 publication Critical patent/KR880001326B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음

Description

1, 2, 3, 4-테트라하이드로이소퀴놀린-3-카복실산의 치환 아실 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 본문에 상술한 바와 같이, 다음 일반식(2)의 적당히 치환된 1,2,3,4-테트라 하이드로 -3-이소퀴놀린 카복실레이트를 다음일 반식치(3) N-치환아미노산과 펩티드 카플링(coupling) 시키고 보호기를 제거하는 것으로 구성된, 다음 일반식(I)의 1,2,3,4-테트라 하이드로-3-이소퀴놀린 카복실산 화합물의 치환 아실 유도체의 제조방법.
    식중
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019810003713A 1980-10-03 1981-10-02 1, 2, 3, 4-테트라하이드로이소퀴놀린-3-카복실산의 치환 아실 유도체 Expired KR880001326B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19376780A 1980-10-03 1980-10-03
US193767 1980-10-03
US236397 1981-02-20
US06/236,397 US4344949A (en) 1980-10-03 1981-02-20 Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids

Publications (2)

Publication Number Publication Date
KR830007567A true KR830007567A (ko) 1983-10-21
KR880001326B1 KR880001326B1 (ko) 1988-07-25

Family

ID=26889329

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810003713A Expired KR880001326B1 (ko) 1980-10-03 1981-10-02 1, 2, 3, 4-테트라하이드로이소퀴놀린-3-카복실산의 치환 아실 유도체

Country Status (23)

Country Link
US (1) US4344949A (ko)
EP (2) EP0096157B1 (ko)
JP (1) JPS5788164A (ko)
KR (1) KR880001326B1 (ko)
AT (2) ATE25974T1 (ko)
AU (2) AU551239B2 (ko)
CA (3) CA1341330C (ko)
DD (1) DD201787A5 (ko)
DE (3) DE3176010D1 (ko)
DK (1) DK163120C (ko)
ES (1) ES8301925A1 (ko)
FI (2) FI78690C (ko)
GR (1) GR75353B (ko)
HK (1) HK43389A (ko)
IE (2) IE52666B1 (ko)
IL (1) IL63806A (ko)
LU (1) LU88321I2 (ko)
MX (1) MX155144A (ko)
MY (1) MY100440A (ko)
NL (2) NL930077I2 (ko)
NO (1) NO159017C (ko)
PH (1) PH17740A (ko)
SG (1) SG15689G (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980086989A (ko) * 1997-05-13 1998-12-05 야코비 치환된 6- 및 7- 아미노-테트라하이드로이소퀴놀린 카복실산

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460775A (en) * 1979-08-09 1984-07-17 Norwich Eaton Pharmaceuticals, Inc. 2-(3-Mercapto-1-oxopropyl)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid derivatives
US4595675A (en) * 1979-09-19 1986-06-17 Hoechst Aktiengesellschaft Bicyclic α-iminocarboxylic acid compounds having hypotensive activity
US4616029A (en) * 1979-12-07 1986-10-07 Adir Perhydromdole-2-carboxylic acids as antihypertensives
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4565819A (en) * 1979-12-07 1986-01-21 Adir Substituted imino diacids, their preparation and pharmaceutical compositions which contain them
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4616030A (en) * 1979-12-07 1986-10-07 Adir Perhydroindole-2-carboxylic acids as antihypertensives
US4644008A (en) * 1979-12-07 1987-02-17 Adir Perhydroindole-2-carboxylic acids as antihypertensives
US4616031A (en) * 1979-12-07 1986-10-07 Adir Perhydroindole-2-carboxylic acids as antihypertensives
DE3177311D1 (de) * 1980-08-30 1994-06-09 Hoechst Ag Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung.
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4532342A (en) * 1981-02-20 1985-07-30 Warner-Lambert Company N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
IN156096B (ko) * 1981-03-19 1985-05-11 Usv Pharma Corp
EP0065301A1 (en) * 1981-05-18 1982-11-24 Merck & Co. Inc. Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same
DE3134933A1 (de) * 1981-09-03 1983-03-31 Hoechst Ag, 6230 Frankfurt "harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente sowie deren verwendung"
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
EP0081094A1 (en) * 1981-11-12 1983-06-15 Merck & Co. Inc. Substituted omega-amino-carboxymethyldipeptide antihypertensive agents
IE55867B1 (en) * 1981-12-29 1991-02-14 Hoechst Ag New derivatives of bicyclic aminoacids,processes for their preparation,agents containing these compounds and their use,and new bicyclic aminoacids as intermediates and processes for their preparation
IE54551B1 (en) * 1982-01-22 1989-11-22 Ici Plc Amide derivatives
US4665087A (en) * 1982-02-22 1987-05-12 Ciba-Geigy Corporation 1-(carbamyl, thiocarbamyl, and iminocarbamyl)-indoline derivatives
US4483850A (en) * 1982-05-10 1984-11-20 Merck & Co., Inc. N-Terminal substituted oligopeptide converting enzyme inhibitors
US4617291A (en) * 1982-05-14 1986-10-14 Mead Johnson & Company Angiotensin-converting enzyme inhibiting dipeptide derivatives
US4427665A (en) 1982-05-19 1984-01-24 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted imino acids and their use in hypotensive compositions
AU560285B2 (en) * 1982-07-19 1987-04-02 Imperial Chemical Industries Plc Heterocyclyl carbonyl sulphonamides
US4500713A (en) * 1982-09-23 1985-02-19 Usv Pharmaceutical Corporation Therapeutic dipeptides
DE3302125A1 (de) * 1983-01-22 1984-07-26 Boehringer Ingelheim KG, 6507 Ingelheim Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung
US4659711A (en) * 1983-01-31 1987-04-21 Usv Pharmaceutical Corporation 1,2,3,4-Tetrahydrophthalazine and hexahydropyridazine compounds for treating hypertension
DE3303344A1 (de) 1983-02-02 1984-08-02 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten aminosaeuren und deren estern
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3333455A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung n-alkylierter dipeptide und deren estern
DE3333454A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern
US4542234A (en) * 1983-10-06 1985-09-17 Usv Pharmaceutical Corp. Process for the separation of (S,S) diastereoisomers
DE3345355A1 (de) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
US4584299A (en) * 1984-05-21 1986-04-22 Warner-Lambert Company Method of treating heart failure and medicaments therefor
GB8422165D0 (en) * 1984-09-01 1984-10-03 Wellcome Found Compounds
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4785089A (en) * 1985-06-13 1988-11-15 Ciba-Geigy Corporation Novel sulfonic acid esters and their preparation
US4652668A (en) * 1985-07-03 1987-03-24 Biomeasure, Inc. Aromatic amino acid derivatives
DE3529960A1 (de) * 1985-08-22 1987-03-05 Boehringer Ingelheim Kg Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0566157A1 (en) 1986-06-20 1993-10-20 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
JP2535001B2 (ja) * 1987-01-13 1996-09-18 ダイセル化学工業株式会社 Ｎ−アルキル化アミノ酸エステルの製法
US5262436A (en) * 1987-03-27 1993-11-16 Schering Corporation Acylamino acid antihypertensives in the treatment of congestive heart failure
US4761479A (en) * 1987-03-30 1988-08-02 Warner-Lambert Company Crystalline quinapril and a process for producing the same
FR2620700B1 (fr) * 1987-09-17 1990-06-01 Adir Procede de synthese d'alpha amino acides n alkyles et leurs esters. application a la synthese de carboxyalkyl dipeptides
FR2620699B1 (fr) * 1987-09-17 1990-06-01 Adir Procede de synthese d'alpha amino acides n alkyles et de leurs esters. application a la synthese de carboxyalkyl dipeptides
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
US5055588A (en) * 1988-07-06 1991-10-08 Daicel Chemical Industries Ltd. Process for preparing N-substituted amino acid esters
US4912221A (en) * 1988-10-27 1990-03-27 Occidental Chemical Corporation Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors and preparation thereof
DD284030A5 (de) 1988-11-24 1990-10-31 Hoechst Ag,De Verfahren zur herstellung von peptiden mit bradykinin-antagonistischer wirkung
ZA902661B (en) * 1989-04-10 1991-01-30 Schering Corp Mercapto-acyl amino acids
US5389610A (en) * 1989-11-21 1995-02-14 Schering Corporation Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
AU7168091A (en) * 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5075302A (en) * 1990-03-09 1991-12-24 Schering Corporation Mercaptoacyl aminolactam endopeptidase inhibitors
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
US5173506A (en) * 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
TW197945B (ko) * 1990-11-27 1993-01-11 Hoechst Ag
TW258739B (ko) * 1992-04-04 1995-10-01 Hoechst Ag
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
GB2266529A (en) * 1992-05-01 1993-11-03 Merck Sharp & Dohme Tetrahydroisoquinoline derivatives
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
ES2165446T3 (es) * 1995-03-13 2002-03-16 Aventis Pharma Gmbh Fosfonomonoester-acidos nucleicos, procedimiento para su preparacion y su utilizacion.
FR2746394B1 (fr) 1996-03-20 1998-05-29 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation, et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
EP0796855B1 (de) 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19612067A1 (de) * 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
ES2122941B1 (es) * 1997-05-29 1999-07-01 Esteve Quimica Sa Procedimiento para la obtencion de quinapril clorhidrato y solvatos utiles para el aislamiento y purificacion de quinapril clorhidrato.
DE19741235A1 (de) * 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
TR200003600T2 (tr) * 1998-06-05 2001-04-20 Warner-Lambert Company ACE inhibitörleri içeren bileşimlerin magnezyum oksit kullanılarak sabitlenmesi
US6538006B1 (en) 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
US6191144B1 (en) 1998-08-17 2001-02-20 Warner-Lambert Company Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis
NZ333206A (en) 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
AU4500200A (en) * 1999-04-30 2000-11-17 Millennium Pharmaceuticals, Inc. Ace-2 inhibiting compounds and methods of use thereof
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
CA2398995C (en) * 2000-02-04 2014-09-23 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
CA2303481A1 (en) * 2000-04-05 2001-10-05 Bernard Charles Sherman Pharmaceutical compositions comprising moexipril magnesium
FR2807430B1 (fr) * 2000-04-11 2002-05-17 Adir Nouveau procede de synthese des esters de la n-[(s)-1- carboxybutyl]-(s)-alanine et application a la synthese du perindopril
WO2002048715A2 (en) 2000-12-14 2002-06-20 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
US6984645B2 (en) * 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
CA2388475C (en) 2002-05-31 2009-12-08 Brantford Chemicals Inc. Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives
BR0313593A (pt) 2002-08-19 2005-07-12 Pfizer Prod Inc Terapia de combinação para doenças hiperproliferativas
US20050101640A1 (en) * 2002-10-16 2005-05-12 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
US20040110241A1 (en) * 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
CA2510773C (en) * 2002-12-16 2010-04-13 Lupin Limited Crystalline form of quinapril hydrochloride and process for preparing the same
US20070218139A1 (en) * 2002-12-20 2007-09-20 Smith Thomas J High Pressure Compaction For Pharmaceutical Formulations
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000541A1 (es) * 2003-03-31 2005-02-04 Warner Lambert Co Procedimiento de preparacion de clorhidrato de quinapril por reaccion entre una 2,5-dioxo-oxazolidina y un ester terbutilico de una tetrahidro isoquinolina, util como principio activo para tratar la hipertension y la insuficiencia cardiaca congestiva
CN1812983A (zh) 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 取代的吡咯衍生物及其作为hmg－co抑制剂的用途
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
HUE027546T2 (en) 2003-08-29 2016-10-28 Brigham & Womens Hospital Inc Hydantoin derivatives as cell necrosis inhibitors
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
EP2174658A1 (en) 2005-05-31 2010-04-14 Mylan Laboratories, Inc Compositions comprising nebivolol
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8080579B2 (en) * 2005-10-03 2011-12-20 The Regents Of The University Of Michigan Compositions and methods for treatment of inflammatory bowel disease
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007069268A2 (en) * 2005-10-14 2007-06-21 Sun Pharmaceutical Industries Limited A process for the preparation of substantially pure 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
SG166829A1 (en) 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP5412273B2 (ja) 2006-03-21 2014-02-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー ペプチド−ぺプチダーゼ阻害剤及びその使用
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN101143846B (zh) * 2006-09-12 2011-02-02 南京新港医药有限公司 喹那普利拉的金属盐
EP2089355A2 (en) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
CN102317786A (zh) 2007-04-18 2012-01-11 特提斯生物科学公司 糖尿病相关性生物学标记物及其使用方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8598314B2 (en) * 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
JP2011503085A (ja) * 2007-11-07 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アンギオテンシン変換酵素阻害剤及びバソプレッシン受容体拮抗薬を含む複合治療
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110190807A1 (en) 2010-02-01 2011-08-04 The Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
WO2011127341A2 (en) 2010-04-08 2011-10-13 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2611403T3 (es) 2011-07-18 2017-05-08 Critical Care Diagnostics, Inc. Procedimientos de tratamiento de enfermedades cardiovasculares y de predicción de la eficacia de terapia de ejercicio
JP5898770B2 (ja) 2011-08-26 2016-04-06 ウォックハート リミテッド 心血管疾患の治療方法
EP2855458B1 (en) 2012-05-11 2018-08-08 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
WO2014022195A1 (en) 2012-08-01 2014-02-06 Tavakoli Zahra Free flowing, frozen compositions comprising a therapeutic agent
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2907765C (en) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2014202659A1 (en) 2013-06-21 2014-12-24 Sanofi-Aventis Deutschland Gmbh Process for the preparation of amides of n-[1-(s)-(ethoxycarbonyl)-3-phenylpropyl]-l-alanine
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2017075232A1 (en) 2015-10-27 2017-05-04 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
HUE069590T2 (hu) 2019-01-18 2025-03-28 Astrazeneca Ab PCSK9-gátló 6'-[[(1s,3s)-3-[[5-(difluormetoxi)-2-pirimidinil]amino]ciklopentil]amino][1(2h ),3'-bipiridin]-2-on és alkalmazására szolgáló eljárások

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691169A (en) * 1970-09-03 1972-09-12 Neisler Lab Inc 2-(alkylthioalkyl)-1,2,3,4-tetrahydroisoquinolines
US3929830A (en) * 1972-08-28 1975-12-30 Velsicol Chemical Corp N-({60 -thiocyanoacetyl)indolines
US4125604A (en) * 1974-11-08 1978-11-14 Mitsubishi Chemical Industries Limited N2-Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4052511A (en) * 1976-02-13 1977-10-04 E. R. Squibb & Sons, Inc. Carboxyacylproline derivatives
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
US4116962A (en) * 1976-12-03 1978-09-26 E. R. Squibb & Sons, Inc. Pyrrolidine and piperidine-2-carboxylic acid derivatives
US4091024A (en) * 1976-12-03 1978-05-23 E. R. Squibb & Sons, Inc. Pyrrolidine and piperidine-2-carboxylic acid derivatives
US4129566A (en) * 1978-02-15 1978-12-12 E. R. Squibb & Sons, Inc. Derivatives of dehydrocyclicimino acids
DE2720966C2 (de) 1977-05-10 1991-09-26 Karl Deutsch Prüf- und Meßgerätebau, 5600 Wuppertal Ultraschallsender
IT7851510A0 (it) 1977-10-28 1978-10-16 Sandoz Ag Ammidi di amminoacidi ciclici loro preparazione e loro applicazione quali medicamenti
CA1120400A (en) 1977-12-27 1982-03-23 Zola P. Horovitz Method of treating hypertension and medicaments therefor
US4154935A (en) * 1978-02-21 1979-05-15 E. R. Squibb & Sons, Inc. Halogen substituted mercaptoacylamino acids
JPS5572169A (en) * 1978-11-27 1980-05-30 Tanabe Seiyaku Co Ltd Isoquinoline derivative and its preparation
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4461896A (en) 1979-02-07 1984-07-24 Norwich Eaton Pharmaceuticals, Inc. 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids
EP0018104B1 (en) * 1979-03-26 1983-05-25 Takeda Chemical Industries, Ltd. Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension
US4294832A (en) * 1979-04-28 1981-10-13 Tanabe Seiyaku Co., Ltd. Tetrahydroisoquinoline compounds and a pharmaceutical composition thereof
GB2048863B (en) 1979-05-16 1983-06-15 Morton Norwich Products Inc Tetrahydroisoquinoline-3-carboxylic acids
US4303583A (en) * 1979-08-13 1981-12-01 American Home Products Corporation 1H,5H-[1,4]Thiazepino[4,3-a]indole-1,5-diones
FR2503155A2 (fr) * 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2487829A2 (fr) * 1979-12-07 1982-02-05 Science Union & Cie Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4251444A (en) * 1980-04-07 1981-02-17 American Home Products Corporation Thiazepino-[4,3-b]-isoquinoline-1,5-dione derivatives and precursors
DE3177311D1 (de) * 1980-08-30 1994-06-09 Hoechst Ag Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980086989A (ko) * 1997-05-13 1998-12-05 야코비 치환된 6- 및 7- 아미노-테트라하이드로이소퀴놀린 카복실산

Also Published As

Publication number Publication date
IE811566L (en) 1982-01-11
DE19575041I2 (de) 2001-11-22
FI79839B (fi) 1989-11-30
GR75353B (ko) 1984-07-13
AU551239B2 (en) 1986-04-24
EP0096157A3 (en) 1984-09-12
ATE25974T1 (de) 1987-04-15
DK163120C (da) 1992-06-15
JPH0316359B2 (ko) 1991-03-05
CA1341330C (en) 2002-01-01
FI881985A0 (fi) 1988-04-27
FI78690B (fi) 1989-05-31
IL63806A (en) 1985-02-28
NL930077I1 (nl) 1993-09-16
IE52666B1 (en) 1988-01-20
NO813359L (no) 1982-04-05
NL930077I2 (nl) 1993-10-01
HK43389A (en) 1989-06-07
EP0049605B1 (en) 1987-03-18
NL960012I2 (nl) 1997-02-03
AU563683B2 (en) 1987-07-16
FI78690C (fi) 1989-09-11
CA1331614C (en) 1994-08-23
DK163120B (da) 1992-01-20
NO159017C (no) 1988-11-23
NL960012I1 (nl) 1996-10-01
NO159017B (no) 1988-08-15
FI79839C (fi) 1990-03-12
IE52665B1 (en) 1988-01-20
EP0096157A2 (en) 1983-12-21
ES505960A0 (es) 1982-12-16
DK436081A (da) 1982-04-04
IE812097L (en) 1982-08-20
ES8301925A1 (es) 1982-12-16
FI813033L (fi) 1982-04-04
AU7541681A (en) 1982-05-06
KR880001326B1 (ko) 1988-07-25
LU88321I2 (fr) 1994-05-04
AU5299186A (en) 1986-07-17
PH17740A (en) 1984-11-23
JPS5788164A (en) 1982-06-01
DD201787A5 (de) 1983-08-10
EP0096157B1 (en) 1987-03-25
DE3176010D1 (en) 1987-04-23
MY100440A (en) 1990-09-29
AU563683C (en) 2001-12-20
DE3176029D1 (en) 1987-04-30
CA1331615C (en) 1994-08-23
FI881985A7 (fi) 1988-04-27
SG15689G (en) 1989-06-09
EP0049605A1 (en) 1982-04-14
US4344949A (en) 1982-08-17
MX155144A (es) 1988-02-01
ATE26120T1 (de) 1987-04-15

Similar Documents

Publication Publication Date Title
KR830007567A (ko) 1, 2, 3, 4-테트라하이드로이소퀴놀린-3-카복실산의 치환아실 유도체의 제조방법.
KR840005083A (ko) 항고혈압제로서 유용한 아미노산유도체의 제조방법
DE68913864D1 (de) Elektronischer Starter eines Motors.
KR830007549A (ko) 2-옥소아제티딘 유도체의 제법
KR830009023A (ko) 피롤리딘 유도체의 제조방법
KR830005863A (ko) 인체 융모성선자격 호르몬의 제조방법
KR890009389A (ko) 바이러스를 억제시키는 방법
KR860007286A (ko) Grf 유도체의 제조방법
KR870001191A (ko) 퀴논론카복실산 유도체의 제조방법
DE68910781D1 (de) Verfahren zur Herstellung eines Emulsionssprengstoffs.
AT387213B (de) Verfahren zur herstellung von neuen 2-amino-3(halogenbenzoyl)-methylphenylessigsaeurederivaten und von phamrazeutischen zubereitungen, welche diese enthalten
KR830003420A (ko) 피롤리딘 유도체
KR870003097A (ko) (+)-6-클로로-5,10-디하이드로-5-[(1-메틸-4-피페리디닐)아세틸]-11H-디벤조 [b,e][1,4] 디아제핀-11-온의 분리방법
KR890012960A (ko) 결정성 β-락탐 용매화물
KR910011788A (ko) 피리딘-n-옥사이드 유도체 및 이의 제조방법
IT7927920A0 (it) Derivati mercaptoacilici di acidi 4,5-diidro-1h-pirrol-2-carbossilici e di acidi 1,4,5,6-tetraidropiridin-2-carbossi lici.
KR910011898A (ko) 데스(64,65)-프로인슐린의 제조방법
KR840008367A (ko) 악타플라닌 항생물질의 제조방법
KR900003201A (ko) 펩티드 및 항치매제
KR830010091A (ko) 구연산 나프티드로푸릴의 제조방법
KR920009792A (ko) 3-아미노-4-메틸렌피롤리딘 유도체의 제조방법
KR890001977A (ko) 피로글루타미드 유도체
AT382374B (de) Verfahren zur herstellung von neuen n-substituierten ergolin- und 9,10-didehydroergolin-8-carboxamid-derivaten
KR920011492A (ko) 시플로플록사신의 주사용 조성물 및 그 제조방법
KR830001203A (ko) N-(1-메틸-2-필로리디닐-메틸)-2,3-디메톡시-5-메틸설파모일 벤즈아미드의 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19811002

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19860827

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19811002

Comment text: Patent Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19880215

Patent event code: PE09021S01D

PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19880623

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19880930

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19881015

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19881015

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19910716

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 19920706

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 19930625

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 19940629

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 19950630

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 19960628

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 19970630

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 19980629

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 19990630

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20000629

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20010707

Start annual number: 14

End annual number: 14

PC1801 Expiration of term